Table 1.
Summary of the HLA-G polymorphisms that have been reported in RIF patients.
| HLA-G polymorphisms | Location | No. studies | Publication | Included in meta-analysis |
|---|---|---|---|---|
| HLA-G genotypes | ||||
| HLA-G 14-bp ins/del (rs66554220/rs371194629) | 3′UTR | 6 | Hviid 2004 (39) Sipak-Szmigie 2009 (42) Enghelabifar 2014 (37) Lashley 2014 (50) Nardi 2016 (35) Nowak 2019 (8) |
Yes |
| HLA-G -725 C>G(T) (rs1233334) | 5′URR | 2 | Sipak-Szmigie 2009 (42) Nowak 2019 (8) |
Yes |
| HLA-G -964G>A (rs1632947) | 5′URR | 1 | Nowak 2019 | No |
| HLA-G haplotypes | ||||
| Haplotypes of rs1632947-rs1233334-rs371194629 | – | 1 | Nowak 2019 (8) | No |
| Haplotypes of HLA-G alleles and rs371194629 | – | 1 | Nardi 2012b (36) | No |
| HLA-G diplotypes | ||||
| Diplotypes of rs1632947–rs1233334–rs371194629 | – | 1 | Nowak 2019 (8) | No |
| HLA-G allele distribution | ||||
| HLA-G*010101 | Exon2-4 | 3 | Kuroshli 2015 (20) Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G*01010106 | Exon2-4 | 1 | Kuroshli 2015 (20) | No |
| HLA-G*010102 | Exon2-4 | 3 | Kuroshli 2015 (20) Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G*010103 | Exon2-4 | 3 | Kuroshli 2015 (20) Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G*010105 | Exon2-4 | 1 | Kuroshli 2015 (20) | No |
| HLA-G*010106 | Exon2-4 | 3 | Kuroshli 2015 (20) Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G*010107 | Exon2-4 | 2 | Kuroshli 2015 (20) Nardi 2012a (19) |
Yes |
| HLA-G*010108 | Exon2-4 | 3 | Kuroshli 2015 Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G*010109 | Exon2-4 | 1 | Sipak-Szmigie 2009 (42) | No |
| HLA-G*010112 | Exon2-4 | 1 | Nardi 2012a (19) | No |
| HLA-G*010114 | Exon2-4 | 1 | Nardi 2012a (19) | No |
| HLA-G*010120 | Exon2-4 | 1 | Nardi 2012a (19) | No |
| HLA-G*0103 | Exon2-4 | 1 | Kuroshli 2015 (19) | No |
| HLA-G*010301 | Exon2-4 | 1 | Nardi 2012a (19) | No |
| HLA-G*010401 | Exon2-4 | 3 | Kuroshli 2015 (20) Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G*010403 | Exon2-4 | 2 | Kuroshli 2015 (20) Nardi 2012a (19) |
Yes |
| HLA-G*010404 | Exon2-4 | 2 | Kuroshli 2015 Nardi 2012a (19) |
Yes |
| HLA-G*0106 | Exon2-4 | 3 | Kuroshli 2015 (20) Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G*01:05N | Exon2-4 | 3 | Kuroshli 2015 (20) Nardi 2012a (19) Sipak-Szmigie 2009 (42) |
Yes |
| HLA-G +482T/C | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +485G/T | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +494A/C | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +505/+506 -/CC | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +506 -/C | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +615 A/- | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +636C/T | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +644G/T | Intron2 | 1 | Kuroshli 2015 (20) | No |
| HLA-G +685G/A | Intron2 | 1 | Kuroshli 2015 (20) | No |
3’UTR, 3 prime untranslated region; 5’URR, 5 prime upstream regulatory region.